ABSTRACT Formyl-methionyl-leucyl-phenylalanine (FMLP), a synthetic, acylated tripeptide analogous to bacterial chemotactic factors, has been shown to cause bronchoconstriction in guinea pig, rabbit, and human airways in vitro. To determine whether FMLP causes bronchoconstriction in man in vivo, a preliminary study was undertaken in which five non-smokers (mean age 35 years, FEV1 94% (SEM 5%) predicted) and five smokers (mean age 34 years, FEV, 93% (6%) predicted) inhaled aerosols of FMLP. None of the subjects showed airway hyperresponsiveness to histamine (the provocative concentrations of histamine causing a fall of > 20% in FEV, (PC20) were over 8 mg/ml). FMLP dissolved in 50% dimethylsulphoxide and 50% saline in concentrations of 0, 0-06, 0-12, 025, 0-5, 1-0, 2-0, and 4-0 mg/ml was administered to the subjects by means of a French-Rosenthal dosimeter, FEV, being recorded after inhalation ofeach concentration. Dose dependent falls in FEV, occurred in five non-smokers (geometric mean 1 76, 95% confidence limits 0-87-3-53 mg/ml) and three smokers (0-23, 0O07-0 78 mg/ml), with two smokers not responding by 20% to the highest concentration of FMLP. On a separate day the FMLP dose-response curves were repeated after nebulisation of 500 ,ug of ipratropium bromide. The PC20 FMLP in the responders more than doubled. In six additional normal subjects a histamine inhalation test was performed before and four and 24 hours after inhalation of FMLP. All subjects remained unresponsive to histamine. These results show that FMLP is a potent bronchoconstrictor in some non-asthmatic individuals in vivo and this may be important in bronchoconstriction related to infection in patients with chronic obstructive lung disease.
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In the present study the dose-response curves were shifted to the right after pretreatment with ipratroprium bromide. Previous results in vitro, however, failed to show inhibition by atropine.'6 Alternatively, the efficacy of the anticholinergic drug in vivo may be related to inhibition of the effects of irritant receptors firing in response to FMLP. Certainly, cough frequently occurred in subjects after FMLP inhalation. The shift to the right of the FMLP-response curve after ipratropium bromide is unlikely to be simply a reflection of bronchodilatation since the subjects had normal baseline lung function and failed to respond to ipratropium bromide when this was tested separately.
Since substance P24 and possibly FMLP25 are vasodilators the flushing reaction observed in the present study may be explained by absorption from the airways of FMLP or systemic release of substance P, or both. We have measured heart rate and blood pressure after FMLP inhalation, however, and did not detect any change. The development of the flushing response at a lower concentration than that required for bronchoconstriction and its non-progressive nature with increasing concentrations of FMLP suggests a mechanism different from that of the bronchoconstriction.
If other mediators play a part, it is difficult to suggest likely possibilities. There is evidence that FMLP produces histamine release from human mast cells in vitro. 26 Airway smooth muscle contraction in vitro in response to FMLP was not, however, inhibited by H, antagonists in man'6 or guinea pig. 27 It has recently been shown that platelet activating factor is released from human polymorphs stimulated with FMLP.28 Synthesis occurred within 25 minutes, however, and release occurred 5 minutes after stimulation. These delayed responses therefore fail to explain the in vivo or in vitro data.
The lack of development of airway hyperresponsiveness after inhalation of FMLP is different from the effect of inhaled chemotactic factors in experimental animals. Irvin et af' recently showed that inhalation of activated complement fragments was followed by hyperresponsiveness to histamine. Lack of hyperresponsiveness may indicate a direct bronchoconstrictor or irritant effect, or both, without the intervention of any effector cells or other mediators.
There are important clinical implications of the findings in this study. During acute infective exacerbation in patients with chronic bronchitis airways resistance increases. This may be due to inflammatory changes in the airways, oedema and mucus causing airway obstruction. Clinically, however, increases in airways resistance are commonly found when sputum becomes coloured and infected even when sputum volumes are not increased. Several potential mechanisms for this observation have been considered in the 39 past, including production of endotoxin by Haemophilus influenzae30 causing bronchoconstriction, enhanced a-adrenergic responsiveness induced by endotoxin in patients with chronic bronchitis,3' and mediator release induced by bacteria.32 Streptococcus pneumoniae is capable of producing chemotactic factors.3 This has not, however, been established for H influenzae. Nevertheless, the demonstration of the potent bronchoconstrictor response to FMLP in the human subjects in vivo raises the possibility that such a mechanism may be operating during infective exacerbations in patients with chronic bronchitis. 
